tweenvest

Hemab Therapeutics Holdings, Inc. (NasdaqGS: COAG)

Health Care · Biotechnology · US

$39.06

+0.01% today · +14.9% 1Y

Public summary
A free snapshot of Hemab Therapeutics Holdings, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Hemab Therapeutics Holdings, Inc. (NasdaqGS: COAG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.83B and employs 59 people.

Over the last twelve months the share price has gained 14.9%, trading between 23.00 and 55.42.

Tweenvest scores Hemab Therapeutics Holdings, Inc. across four factors: quality 46/100, value 100/100. Its strongest factor is value.

COAG price history

May 1, 2026 · 34.00Weekly closes 24.98 – 54.94Nov 17, 2026 · 39.06

Key figures

Market cap
$1.83B
Revenue (TTM)
—
P/E
-37.48
EPS
-67.56
Dividend yield
—
Beta (5Y)
—
52-week high
$55.42
52-week low
$23.00
Avg volume (3M)
—
Shares outstanding
46.73M
Employees
59
Next earnings
—

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.

ISIN
US4234941031
Founded
2020
Listed since
May 1, 2026
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
Replimune Group, Inc.NasdaqGS: REPL$1.88B$19.81+0.61%
Zenas BioPharma, Inc.NasdaqGS: ZBIO$1.87B$27.64-3.69%
Anhui Anke Biotechnology (Group) Co., Ltd.SZSE: 300009$1.87BCN¥7.47-1.19%
Zymeworks Inc.NasdaqGS: ZYME$1.85B$26.86+3.15%
Sino Biological,Inc.SZSE: 301047$1.81BCN¥99.20-11.02%
Genus plcLSE: GNS$1.79B£21.26-1.39%
Pell Bio-Med Technology Co., Ltd.TWSE: 6949$1.79BNT$45.00+9.89%
Lycia Therapeutics, Inc.NasdaqGS: LYCA$1.78B$30.92+8.07%

Browse every Biotechnology company →